Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30942486 | 0.98 | APLNR (0.42) | APLNRKDM1AMAOB | |
| SCHEMBL20231857 | 0.89 | APLNR (0.39) | APLNR | |
| SCHEMBL30984827 | 0.84 | APLNR (0.34) | APLNR | |
| SCHEMBL904094 | 0.84 | APLNR (0.30) | APLNR | |
| SCHEMBL10262814 | 0.84 | — | — | |
| Trifluoroacetic Acid SCHEMBL27041888 | 0.83 | APLNR (0.36) | APLNR | |
| Hydrochloric Acid SCHEMBL27086578 | 0.82 | — | — | |
| SCHEMBL22835375 | 0.81 | — | — | |
| SCHEMBL26088513 | 0.79 | APLNR (0.48) | APLNR | |
| SCHEMBL19745093 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626554-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | Tiger Biotherapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| CN-118812564-A | EGFR-targeting proteolytic targeting chimeras, compositions and uses thereof | 厦门宝太生物科技股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2024146502-A1 | WEE1 DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2024-07-11 | — | — | WO | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024118960-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024020522-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020522-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-117157298-A | Dual-function chimeric heterocyclic compound of interleukin-1 receptor related kinase 4, preparation method, medicinal composition and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023186069-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-10-05 | — | — | WO | disclosed |
| CN-114206872-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR8 agonists | 百济神州有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-112321590-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR8 agonists | 百济神州有限公司 | 2021-02-05 | — | — | CN | disclosed |
| WO-2012041158-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | APLNR 4023/4885KDM1A 1685/4885MAOB 4126/4885 |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | KRAS, VHL, HRAS | APLNR 4023/4885KDM1A 1685/4885MAOB 4126/4885 |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | APLNR 2754/4885KDM1A 1307/4885MAOB 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.